Right on Target: Clinical Genomics Identifies Cancer Patients Likely to Benefit from Targeted Therapies

Genomics screening can improve the odds for some cancer patients, potentially identifying mutations associated with cancer subtypes for which targeted therapies exist or are in development. In appropriately selected patients, response rates for targeted therapies are often higher than for conventional chemotherapy.

More at Progressnotes, MUSC’s Medical Magazine